Lantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) ...

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma ...

DUBLIN--(BUSINESS WIRE)--The "Positron Emission Tomography (PET) Scanners - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global market for Positron ...

The Food and Drug Administration (FDA) has approved Tauklarify ™ (florquinitau F 18 injection) for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being ...

Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group In ...

Lantheus Holdings (LNTH) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer’s disease through positron ...

A PET imaging study reveals 65% of late-onset psychosis patients have tau protein accumulation linked to dementia.

KNOXVILLE, Tenn.-- (BUSINESS WIRE)--Aug 14, 2026-- ...

Food and Drug Administration has approved ‌a radioactive agent from Lantheus ‌Holdings for use in brain scans to ​help assess ...

What Is a PET Scan? A positron emission tomography (PET) scan is a type of imaging study that can help doctors see what’s happening inside your body and how it’s working. This can help them understand ...